echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Nat Commun: Gene therapy can be effective for decades

    Nat Commun: Gene therapy can be effective for decades

    • Last Update: 2021-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    March 19, 2021 //---Recently, the international cooperation between Great Ormond Street Hospital, UCL GOS Institute for Child Health and Harvard Medical School has shown that the benefits of gene therapy can be eliminated by the body in transplanted blood stem cells It won’t be seen until decades later.

    The research team monitored five patients who successfully cured SCID-X1 through GOSH gene therapy.
    From 3 to 18 years, the patient’s blood is analyzed regularly to detect which cell types and biomarker chemicals are present in the blood.
    The results show that even if the patient has eliminated the stem cells transplanted as part of the gene therapy vector, the corrected T cells are still being formed.



    (Image source: www.
    pixabay.
    com)

    The working principle of gene therapy is to first remove some hematopoietic stem cells from the patient.
    These stem cells produce various types of blood and immune cells.
    Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
    These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
    In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
    The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
    They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
    The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
    (Bioon.
    com)
    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9



    (Image source: www.
    pixabay.
    com)

    The working principle of gene therapy is to first remove some hematopoietic stem cells from the patient.
    These stem cells produce various types of blood and immune cells.
    Next, in the laboratory, a viral vector is used to deliver a new copy of the defective gene into the DNA of the patient's cells.
    These corrected stem cells are then returned to the patient in a so-called "autologous transplantation" method, and then continue to produce healthy immune cells that can fight infection.
    In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
    The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
    They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
    The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
    (Bioon.
    com)
    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9



    In SCID-X1 gene therapy, the corrected stem cells are finally eliminated by the human body, but the patient can still be cured.
    The research team believes that the "cure" is due to the fact that the human body can continue to produce engineered T cells, which are an important part of the human immune system.
    They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
    The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
    (Bioon.
    com)
    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9


    They used the latest gene tracking technology and a large number of testing methods to conduct an unprecedented detailed study on the T cells of SCID-X1 patients decades after gene therapy.
    The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
    (Bioon.
    com)
    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9


    The research team believes that this gene therapy creates ideal conditions for the human thymus, allowing it to store progenitor cells that can form new T cells for a long time.
    (Bioon.
    com)
    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9

    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9

    Information source: com/news/2021-03-cellular-benefits-gene-therapy-decades.
    html">Cellular benefits of gene therapy seen decades after treatment

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9

    Original source: Natalia Izotova et al, Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications (2021).
    DOI: 10.
    1038/s41467-021-21834-9
    Original source: Long-term lymphoid progenitors independently sustain naïve T and NK cell production in humans, Nature Communications

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.